Primary prostate cancer is generally treatable by androgen deprivation therapy, however,
later recurrences of castrate-resistant prostate cancer (CRPC) that are more difficult to treat …

The phosphoprotein phosphatases are emerging as important androgen receptor (AR)
regulators in prostate cancer (PCa). We reported previously that the protein phosphatase 1 …

Earlier we identified PPP2CA, which encodes for the α-isoform of protein phosphatase 2A
(PP2A) catalytic subunit, as one of the downregulated genes in androgen-independent …

Metastatic prostate cancers generally rely on androgen receptor (AR) signaling for growth
and survival, even following systemic androgen-deprivation therapy (ADT). However, recent …

Androgens and androgen receptors play essential roles in the development and
progression of prostate cancer, a disease that claims roughly 28,000 lives annually. In …

Inhibitor 2 of protein phosphatase 2A (I2PP2A), a biological inhibitor of the cellular
serine/threonine protein phosphatase PP2A, is associated with numerous cellular processes …

The mitogen-activated protein kinase (MAPK) pathway is frequently aberrantly activated in
advanced cancers, including metastatic prostate cancer (CaP). However, activating …

Resistance to androgen receptor (AR) blockade in castration-resistant prostate cancer
(CRPC) is associated with sustained AR signaling, including through alternative splicing of …

Loss of the tumor suppressive activity of the protein phosphatase 2A (PP2A) is associated
with cancer, but the underlying molecular mechanisms are unclear. PP2A holoenzyme …

Protein phosphatase 2A (PP2A) is a tumor suppressor complex that has recently been
reported as a novel and highly relevant molecular target in prostate cancer (PCa). However …